L & C Bio

Seongnam-si, South Korea Founded: 2011 • Age: 15 yrs
Developer of allograft and xenograft technologies
Annual revenue $48.9M Latest available
Total funding - Funding intelligence
Employees 135 Tracked headcount
Investors - Known backers
Products - Services tracked
Competitors 9 Brand Intelligence

About L & C Bio

L & C Bio is a company based in Seongnam-si (South Korea) founded in 2011. The company has 135 employees as of December 31, 2024. L & C Bio operates in a competitive market with competitors including Bio Rad, Siemens Healthineers, Merck, Quanterix and Biocare Medical, among others.

  • Headquarter Seongnam-si, South Korea
  • Employees 135 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Legal Name L&C Bio Co., Ltd.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $48.88 M (USD)
    9.35
    as on Dec 31, 2024
  • Net Profit
    $95.64 M (USD)
    191.69
    as on Dec 31, 2024
  • EBITDA
    $5.75 M (USD)
    -33.26
    as on Dec 31, 2024
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    135

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of L & C Bio

L & C Bio is a publicly listed company on the KRX with ticker symbol 290650 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: KRX · Ticker: 290650 · Sector: Health technology · South Korea

Funding Insights of L & C Bio

Premium access

Detailed funding history for L C Bio

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by L & C Bio

Investments
Premium access

Investment portfolio details for L C Bio

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - L C Bio

Premium access

Detailed financials for L C Bio

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

L & C Bio Comparisons

L & C Bio Primary company
Description
Developer of allograft and xenograft technologies
Location
Seongnam-si, South Korea
Founded Year
2011
Annual Revenue
$48.88 M (USD)
Net Profit
$95.64 M (USD)
EBITDA
$5.75 M (USD)
Employees
135
As of 2024
Premium access

Peer comparison for L C Bio

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of L & C Bio

L & C Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Bio Rad, Siemens Healthineers, Merck, Quanterix and Biocare Medical, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Portfolio of products and services for life science research and clinical diagnostic markets
Locked Locked Locked
AI-based medical diagnostics are developed for healthcare applications.
Locked Locked Locked
Merck is engaged in science and technology solutions globally.
Locked Locked Locked
Assay kits for ultra-sensitive biomarker detection are developed.
Locked Locked Locked
Primary antibodies and instruments for immunohistochemistry are manufactured.
Locked Locked Locked
Tissue hypothermic storage and cryopreservation freeze media are developed.
Premium access

Detailed competitors of L C Bio

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on L & C Bio

Premium access

Complete news archive for L C Bio

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about L & C Bio

L & C Bio was founded in 2011.

L & C Bio is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.

As of Dec 31, 2024, the latest employee count at L & C Bio is 135.

Annual revenue of L & C Bio is $48.88M as on Dec 31, 2024.

L C Bio was founded in 2011 and is based in Seongnam-si, South Korea. Allograft and xenograft solutions are developed across tissue engineering, medical devices, and cosmeceuticals. Manufacturing facilities are certified under ISO 9001 and GMP standards. Biomaterials for tissue repair, collagen-based supplements, implantable biomaterial bones, deep wound coverings, and bioabsorbable wound materials are produced. Operations focus on biomedical innovations for implantation and repair applications.

L & C Bio's top competitors include Biocare Medical, Merck and Siemens Healthineers.

Yes, L & C Bio is publicly traded on KRX under the ticker symbol 290650.

The ticker symbol of L & C Bio is 290650 on KRX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available